Serum levels of the IL-6 family of cytokines predict prognosis in renal cell carcinoma (RCC)
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Purpose: An improved understanding of RCC immunology should shed further light on RCC tumor biology. Our objective was to study to what extent serum levels of the IL-6 family of cytokines at diagnosis were relevant to survival. Methods: A total of 118 consecutively patients with RCC, in which the tumor was surgically removed at Haukeland University Hospital during the period from 2007 to 2010, were included. The patients were followed-up for 10 years. The morning before surgery blood was sampled and serum frozen, with levels of IL-6, IL-27, IL-31, OSM, CNTF, IL-6Rα and gp130 determined. Results: Among patients with the highest quartile of IL-6 (> 8 pg/ml) (n = 29), six of nine who had metastasis at diagnosis had such high IL-6 values. Among presumed radically treated patients, a high IL-6 and IL-27 strongly predicted recurrence. In particular, the predictions among patients with large (diameter > 7 cm) tumors were excellent regarding both IL-6 and IL-27 values. High gp130 serum levels predicted an overall survival (OS) among RCC patients with large tumors. Patients with a high IL-6 exhibited a strong expression of IL-6 in endothelial- and vascular smooth muscle cells. Moreover, the level of intra-tumoral CD3-positive cells predicted survival. Conclusions: IL-6 and IL-27 seem to play a role in RCC biology. IL-6 enables the pinpointing of metastatic condition at diagnosis, as well as together with IL-27, the predicting of survival and recurrence. Endothelial cells and vascular smooth muscle cells are both suggested as important sources of IL-6.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Fig. 4 Overall survival (OS) Kaplan–Meier curve predictions from IL-6 and the family molecules IL-27 and gp130 by Luminex in serum collected before the surgical treatment of RCC patients. The blue continuous line visualizes low values (lower quartiles), with the high values in the red dotted line. Log-rank test p values are included in the separate windows. a IL-6 OS prediction among 118 RCC patients (low (< 8 pg/ml): n = 89 and high (≥ 8 pg/ml): n = 29). b IL-27 prediction of OS in 97 RCC patients (low: n = 73 and high: n = 24). c OS prediction from IL-6 in medium-sized [(4.1–7 cm, n = 37), n = 42] RCCs. Twenty-seven patients were designated as low, with 10 patients having a value within the highest quartile. d Prediction of OS from quartiled gp130 in RCC patients with a tumor size exceeding 7 cm (low: n = 26 and high: n = 4). e IL-6 OS prediction in large (> 7 cm, n = 42) RCC tumors; 28 high value patients and 14 with a low value](https://figures.cochat.ai/paper-figures/cb4832929b2b4c919d408416ed814865/serum-levels-of-the-il-6-family-of-cytokines-predict-prognosis-in-renal-cell-figure-4.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · cited 1×
“In 2018, 175,098 deaths by RCC were estimated, making it the 14th most common cause of global cancer deaths [2].”
BackgroundAllemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C. J., Estève, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33326-3 · Cited by 6,145 · cited 1×
“Cancer diseases are major global killers of humans [1]; thus, there is an urgent need to better understand these diseases.”
BackgroundPrognostic significance of morphologic parameters in renal cell carcinoma
Fuhrman, S. A., Lasky, L. C., & Limas, C. (1982) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198210000-00007 · Cited by 2,724 · cited 1×
“Patients were staged according to the 2009 TNM classification system, and the tumor histology was graded according to the Fuhrman nuclear criteria [23].”
MethodYang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697 · cited 1×
“, VEGF inhibitors [37], as well as with anti-IL-6 therapy such as Siltuximab [38].”
BackgroundVascular Endothelial Growth Factor
Ferrara, N. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.179663 · Cited by 1,283 · cited 1×
“Endothelial cells are presumably stimulated by VEGF from the tumor [31], with this representing a possible loop where the tumor may become autocrine stimulated.”
BackgroundRecent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
Jones, S. A., & Jenkins, B. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0066-7 · Cited by 1,102 · cited 2×
“The receptor signaling complexes for IL-6 and IL-11 contain a gp130 homodimer, whereas other family members signal via a heterodimeric receptor complex containing gp130 [13].”
BackgroundIL-6/IL-6 receptor system and its role in physiological and pathological conditions
Mihara, M., Hashizume, M., Yoshida, H., Suzuki, M., & Shiina, M. (2012) · Clinical Science · doi:10.1042/cs20110340 · Cited by 895 · cited 2×
“, macrophages, Th2 cells, B cells, astrocytes, endothelial cells, adipocytes and some tumor cells [6].”
BackgroundInterleukin-6 Family Cytokines
Rose-John, S. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028415 · Cited by 799 · cited 1×
“These cytokines are collectively named the IL-6 family of cytokines [8, 12], which has several members, including IL-11, IL-27, IL-31, ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), oncostatin M (OSM) and cardiotrophin-like cytokine factor 1 (CLC) [13].”
BackgroundIL-6 and related cytokines as the critical lynchpins between inflammation and cancer
Taniguchi, K., & Karin, M. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.01.001 · Cited by 716 · cited 2×
“These findings support that a high cytokine value points to a biologically aggressive tumor, more than a low differentiated tumor [8, 10, 24].”
BackgroundPleiotropy and specificity: insights from the interleukin 6 family of cytokines
Murakami, M., Kamimura, D., & Hirano, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.027 · Cited by 533 · cited 1×
“Soluble gp130 binds the soluble IL-6/IL-6Rα complex [29], and presumably acts as an IL-6/IL-6Rα decoy receptor [28].”
Background
Cited by
Kartikasari, A. E. R., Huertas, C. S., Mitchell, A., & Plebanski, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.692142 · Cited by 343
“For example in renal cell carcinoma, a high IL-6 correlates to cancer metastasis, while high IL-6 and IL-17 measurements predict cancer recurrence following radical treatment (98).”
BackgroundLi, M., Li, L., Zheng, J., Li, Z., Li, S., Wang, K., & Chen, X. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01745-7 · Cited by 93
“Meanwhile, IL-8 binds to IL-8R to recruit immune cells to influence the tumor microenvironment (TME), thereby inhibiting anti-tumor immune function [121].”
BackgroundInfluentialInflammatory Networks in Renal Cell Carcinoma
Kruk, L., Mamtimin, M., Braun, A., Anders, H., Andrassy, J., Gudermann, T. W., & Mammadova‐Bach, E. (2023) · Cancers · doi:10.3390/cancers15082212 · Cited by 62
SERS-based self-calibrating aptamer sensor for selective detection of IL-6
Huang, Q., Chen, X., Fan, M., Ruan, S., Peng, S., You, R., Chen, J., & Lu, Y. (2022) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2022.132828 · Cited by 42
Rappold, P. M., Vuong, L. H., Leibold, J., Chakiryan, N. H., Curry, M., Kuo, F., Sabio, E. Y., Jiang, H., Nixon, B. G., Liu, M., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0925 · Cited by 38
Metadata
- Authors
- Gudbrandsdottir, G., Aarstad, H. H., Bostad, L., Hjelle, K. M., Aarstad, H. J., Bruserud, Ø., Tvedt, T. H. A., & Beisland, C.
- Affiliations
- University of Bergen (NO)
- Haukeland University Hospital (NO)
- ORCID
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2020-07-03
- Volume
- 70
- Issue
- 1
- Pages
- 19-30
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC7838134
- OpenAlex
- W3038844630
- Cited by
- 35
- References
- 46
- Citations by year
- 2025: 5 · 2024: 5 · 2023: 9 · 2022: 8 · 2021: 8
- FWCI
- 3.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
- Funders
- Universitetet i Bergen
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Keywords
- renal cell carcinoma, interleukin-6, IL-27, IL-6 family cytokines, serum cytokine levels, prognostic factors, overall survival, tumor recurrence, metastasis, tumor size, endothelial cells, vascular smooth muscle cells, IL-6 receptor alpha, gp130, ciliary neurotrophic factor, OSM, IL-31
- MeSH terms
- Aged, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Muscle, Smooth, Vascular, Prognosis, Interleukin-6, CD3 Complex, Myocytes, Smooth Muscle, Endothelial Cells, Interleukin-27
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serum levels of the IL-6 family of cytokines predict prognosis in renal cell carcinoma (RCC). https://app.cochat.ai/papers/10.1007/s00262-020-02655-z
- The paper
- Gudbrandsdottir, G., Aarstad, H. H., Bostad, L., Hjelle, K. M., Aarstad, H. J., Bruserud, Ø., Tvedt, T. H. A., & Beisland, C. (2021). Serum levels of the IL-6 family of cytokines predict prognosis in renal cell carcinoma (RCC). Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-020-02655-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.